Options Trading News

December 11, 2012  Tue 8:56 AM CT

Pharmacyclics is rising today after test results on a key cancer drug, and one trader is betting against a collapse in the biopharmaceutical stock.

optionMONSTER's tracking systems detected the sale of 2,000 May 36 puts in one print for $1. Open interest in the strike was just 36 contracts at the start of the session, so this is a new position.

PCYC is up 2.89 percent to $60.50 this morning after popping at the open. The company today reported positive findings in its Phase II trial of its ibrutinib drug, a proposed oral treatment for a form of lymphoma.

The stock gapped down from above $61 at the beginning of November but has been climbing since then. It rose above its 50-day moving average yesterday and above its 100-day average today.

Today's put seller is betting that PCYC will hold above the $36 strike price through expiration in mid-May 2013. The trader faces the obligation to buy the shares if the stock is below that level, but at an effective price of $35 once the credit from the put sale is included. (See our Education section)
Share this article with your friends



The fastest money in the market
View full report »

Premium Services

Archived Webinar

Education & Strategy

The covered call and unhedged risk

I have written a few things on the Covered Call Strategy over the last two weeks. Please understand that those two previous articles plus this one do not constitute a proper, fully in-depth lesson on the Covered Call Strategy like we have in our classes at Option Monster Education. I have picked out a few topics that I believe were worth noting and today I am going to add the final one.

View more education articles »